Article Alert: ATR Inhibition Enhances anti-PD-L1-based Immunotherapy Through Different Mechanisms

Article Alert: ATR Inhibition Enhances anti-PD-L1-based Immunotherapy Through Different Mechanisms

 

The kinase Ataxia telangiectasia and Rad3-related (ATR) regulates the DNA damage replication stress response (RSR) and promotes cell survival by preventing replication origin firing in the presence of compromised replication forks. Ceralasertib is a selective ATR inhibitor in clinical development that has demonstrated therapeutic promise for a number of malignancies in combination with the anti-PD-L1 agent durvalumab. However, the mechanism(s) that dictate the effects of ATR inhibition on immune cells and the tumor immune microenvironment (TIME) were undefined. 

A novel study by Hardaker et al. contributes new insight into how ATR inhibition (i.e., ceralasertib) potentiates anti-PD-L1 therapy (1). Using mouse tumor models, the authors found that CD8+ T cells were required for the antitumor activity of ceralasertib and that intermittent dosing is required to allow T cell recovery. Ceralasertib also induced systemic changes in the immune cell milieu, including depletion of suppressive monocytic-MDSCs and tumor-associated macrophages (TAMs), an increase of activated dendritic cells, and enhanced PD-1 expression on T cells. In addition, the ATR inhibitor activated Type I interferon (IFNI) signaling in both tumor-bearing mice and cancer patients, which appears to mediate the antitumor action of a combined regimen with an anti-PD-L1 agent. In summary, Hardaker et al. have identified how ATR inhibition leads to activation of the immune response through cellular reprogramming and stimulation of IFNI-mediated signaling that impacts both normal and neoplastic components of the TIME. 

GeneTex offers an extensive catalog of quality antibodies and reagents for immunology research, immune checkpoints, and cancer research, including the ATR (phospho Thr1989) antibody (GTX128145) cited in the Hardaker et al. study. In addition, GeneTex wants to introduce its new recombinant rabbit monoclonal ATR (phospho Thr1989) antibody [HL1836] (GTX637561). For more information, please see the product images below and visit www.genetex.com.

 

Highlighted Products

Recombinant Citation-Support KOKD-Validation Comparable Abs Orthogonal Validation Protein Overexpression 
ATR (phospho Thr1989) antibody (GTX128145)

ATR (phospho Thr1989) antibody (GTX128145)

Citation-SupportKOKD-ValidationOrthogonal Validation
ATR (phospho Thr1989) antibody [HL1836] (GTX637561)

ATR (phospho Thr1989) antibody [HL1836] (GTX637561)

RecombinantOrthogonal Validation
PD-L1 antibody [HL1041] (GTX635975)

PD-L1 antibody [HL1041] (GTX635975)

RecombinantCitation-SupportKOKD-ValidationComparable AbsOrthogonal ValidationProtein Overexpression
 
CTLA4 antibody [HL2732] (GTX639560)

CTLA4 antibody [HL2732] (GTX639560)

Recombinant
CD28 antibody [HL1589] (GTX637068)

CD28 antibody [HL1589] (GTX637068)

RecombinantOrthogonal Validation
TIGIT antibody [HL2657] (GTX639116)

TIGIT antibody [HL2657] (GTX639116)

RecombinantOrthogonal ValidationProtein Overexpression
 

 

Reference:

  1. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4.